搜索
 > 【TNFSF11】重组蛋白信息

TNFSF11信息

英文名称:Tumor necrosis factor ligand superfamily member 11
中文名称:肿瘤坏死因子配体超家族成员11
靶点别称:Osteoprotegerin ligand,CD_antigen=CD254,Tumor necrosis factor ligand superfamily member 11,ODF,Tumor necrosis factor ligand superfamily member 11, membrane form,Osteoclast differentiation factor,TNFSF11,TRANCE,RANKL,Tumor necrosis factor ligand superfamil
上市药物数量:1
临床药物数量:22
最高研发阶段:批准上市

TNFSF11 Molecule Synonym Name

RANKL,CD254,TRANCE,OPGL,ODF

TNFSF11 分子背景

Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.

TNFSF11 参考文献

TNFSF11上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Denosumab 地舒单抗 AMG-162; NSC-744010,AMG162 批准上市 安进, 第一三共 denosumab ema

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.

Treatmen

Amgen Europe B.V. 2010-05-26 骨癌, 骨转移性实体瘤, 实体瘤, 多发性骨髓瘤, 巨骨细胞瘤, 高钙血症, 类风湿性关节炎, 骨质疏松症 详情

TNFSF11临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
ALX-0141 ALX-0141; EDP-406 临床一期 Ablynx, 亿腾医药 骨疾病, 绝经后骨质疏松症
Recombinant human anti-RANKL antibody(Shanghai Henlius Biotech) HLX14,HLX-14 临床一期 上海复宏汉霖生物技术股份有限公司 绝经后骨质疏松症 详情
RPH-203 RPH-203 临床一期 R-Pharm 骨癌, 骨质疏松症
Recombinant human anti-RANKL antibody (Innovent Biologics) IBI-307,IBI307 临床一期 信达生物制药(苏州) 骨质疏松症
APX-008 APX-008 临床前 Epitomics, Apexigen 骨疾病
Recombinant anti-RANKL human monoclonal antibody (Salubris) 临床申请 信立泰 癌症
Denosumab biosimilar (Sandoz) GP-2411 临床三期 山德士, 诺华 绝经后骨质疏松症 详情
Denosumab biosimilar (Intas Biopharmaceuticals) 临床三期 Intas Biopharmaceuticals 绝经后骨质疏松症
Recombinant aiti-RANKL human monoclonal antibody (Kunming Pharmaceutical) 临床申请 昆药集团 癌症
JMT103 JMT-103,JMT103; JMT 103 临床一期 上海津曼特生物科技, 石药集团 骨质疏松症 详情
Denosumab biosimilar (AryoGen) 临床三期 AryoGen Biopharma 绝经后骨质疏松症 详情
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) 临床三期 齐鲁制药 绝经后骨质疏松症
Recombinant human anti-RANKL antibody (Alphamab) KN-012,KN012 临床申请 苏州康宁杰瑞生物科技 骨质疏松症
Recombinant human anti-RANKL momoclonal antibody (Hualan Biological Engineering) 临床一期 华兰基因工程 骨转移性实体瘤
GB-223 GB-223,GB223 临床一期 嘉和生物药业 骨转移性实体瘤, 巨骨细胞瘤, 绝经后骨质疏松症 详情
Denosumab biosimilar (Qilu Pharma) QL-1206 临床三期 齐鲁制药 骨转移性实体瘤 详情
Denosumab biosimilar (Boan Biopharma/Luye Pharma) LY-01011; LY-06006,LY 01011; LY 06006 临床三期 山东博安生物, 绿叶制药 骨转移性实体瘤, 多发性骨髓瘤, 绝经后骨质疏松症, 骨质疏松症 详情
CEP-37251 ART-010; CEP-37251; EGX-010 临床一期 梯瓦 骨质疏松症 详情
LZM-004 LZM-004,LZM004 临床一期 丽珠集团丽珠制药厂 骨转移性实体瘤, 骨质疏松症
AP-002 AP-003; AP-002; LX-001 临床二期 Altum Pharmaceuticals 实体瘤 详情
Recombinant human anti-RANKL antibody (Hisun Pharma) HS629 临床一期 浙江海正药业 骨转移性实体瘤
Recombinant human anti-RANKL antibody (Jiangsu T-mab BioPharma) TK-006; MW032; MW031,TK006 临床三期 江苏泰康生物医药有限公司 骨转移性实体瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定